🎁 Black Friday: 50% off Unlimited and 30% off Pro annual plans
Rapport Therapeutics, Inc. (RAPP)
NASDAQ: RAPP · Real-Time Price · USD
23.16
-0.43 (-1.82%)
At close: Nov 20, 2026, 4:00 PM EST
23.16
0.00 (0.00%)
After-hours: Nov 20, 2026, 7:30 PM EST

Rapport Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22
Selling, General & Admin
38.9130.3122.128.181.37
Research & Development
94.7994.7960.94284.49
Operating Expenses
133.7125.183.0636.185.85
Operating Income
-167.62-125.1-83.06-36.18-5.85
Interest Expense
-----0.31
Interest & Investment Income
17.1513.6212.142.53-
EBT Excluding Unusual Items
-150.47-111.48-70.92-33.65-6.17
Other Unusual Items
---7.39-1.12-
Pretax Income
-150.47-111.48-78.31-34.78-11.62
Income Tax Expense
---0.01-
Net Income
-150.47-111.48-78.31-34.79-11.62
Net Income to Common
-150.47-111.48-78.31-34.79-11.62
Net Income Growth
-----
Shares Outstanding (Basic)
47392121
Shares Outstanding (Diluted)
47392121
Shares Change
31.77%87.74%1277.25%93.74%-
EPS (Basic)
-3.18-2.86-3.78-23.10-14.95
EPS (Diluted)
-3.18-2.86-3.78-23.10-14.95
EPS Growth
-----

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22
Free Cash Flow
-121.18-88.09-67.23-28.82-3.85
Free Cash Flow Per Share
-2.56-2.26-3.24-19.14-4.95
EBITDA
-166.71-124.08-82.22-36.07-5.84
D&A For EBITDA
0.91.020.840.110.02
EBIT
-167.62-125.1-83.06-36.18-5.85
SEC Filings: 10-K · 10-Q